Answer
Firmagon (degarelix acetate) is indicated for adult men with advanced hormone-dependent prostate cancer, and for high-risk localised or locally advanced hormone-dependent prostate cancer in combination with radiotherapy or as neoadjuvant treatment before radiotherapy.
Sources for this answer
- Firmagon 80mg InjectionFerring Pharmaceuticals Ltd · emc · SmPC §4.1 Therapeutic Indications · Version 15Document updated
Sources checked